BeiGene, Ltd. — Q2 2016 Form 10-Q
Company identification: The filing is for BeiGene, Ltd., although the request identifies Beone Medicines Ltd. The reporting period ended June 30, 2016; the filing was signed August 10, 2016. Dollar amounts below are U.S. dollars, generally shown in millions.
Business context and reporting period
BeiGene was a clinical-stage oncology biopharmaceutical company with no approved products and no product-sale revenue. Its principal clinical candidates were BGB-3111, BGB-A317, BGB-290 and BGB-283. Revenue was primarily collaboration revenue from Merck KGaA. The unaudited interim statements were prepared under U.S. GAAP.
Financial performance and liquidity
- Q2 revenue: $0.393 million, down from $1.380 million in Q2 2015. First-half revenue: $1.070 million, down from $2.759 million. The company attributed the decrease principally to ending recognition of BGB-290 ex-China collaboration revenue after repurchasing those rights in October 2015.
- Q2 2016 net loss: $24.124 million, versus $5.641 million in Q2 2015. First-half net loss: $46.125 million, versus $15.853 million. First-half loss per ordinary share was $0.13, compared with $0.15 in 2015; per ADS it was $1.66 versus $1.90.
- Operating expenses: Q2 research and development expense was $21.117 million (up from $6.737 million) and general and administrative expense was $3.904 million (up from $1.208 million). For the first half, R&D was $38.994 million (up from $16.796 million) and G&A was $7.038 million (up from $2.340 million). Increases reflected pipeline advancement, hiring, and public-company and other administrative costs.
- Cash flow: First-half operating cash use was $39.097 million, compared with $13.202 million in 2015. Investing cash use was $95.205 million, mainly reflecting net purchases of short-term securities and $8.758 million of property and equipment. Financing provided $174.570 million, principally from the IPO.
- Cash and liquidity: At June 30, cash and cash equivalents were $58.084 million and short-term investments were $168.535 million, totaling $226.619 million, compared with $100.486 million at year-end 2015. Management said this was expected to fund operating expenses and capital needs for at least 12 months, while cautioning that assumptions could prove wrong.
- Balance sheet and debt: Total assets were $251.230 million; total liabilities were $31.183 million. The company had $10.553 million of long-term bank debt, bearing 7% fixed interest and secured by future equipment purchases and rights to a PRC drug-candidate patent; principal was scheduled for repayment in 2018 and 2019. The senior promissory note was converted into shares at the IPO.
- Margins: The filing reports no product sales or gross profit; a product gross margin is therefore not applicable. Operating loss was $24.628 million in Q2 and $44.962 million for the first half.
Material changes, outlook and risks
- BeiGene completed its IPO on February 8, 2016, raising $166.2 million net. Preferred shares and the senior promissory note converted into ordinary shares; the preferred-share balance was reclassified to equity. The company reported 427.9 million ordinary shares outstanding at June 30.
- Management expected R&D and G&A expenses and operating losses to rise as clinical programs, research, manufacturing investment, hiring and public-company costs expanded. It anticipated no significant product revenue unless and until candidates receive approval and are commercialized. No earnings guidance was provided.
- The company said additional financing would be required to complete global development and potential commercialization of its candidates, despite its stated 12-month liquidity runway. Funding may require equity, debt, collaborations or licensing, with possible dilution or relinquishment of rights.
- Key development risk: the company had temporarily suspended new patient accrual in the China BGB-283 dose-escalation trial to evaluate more frequent thrombocytopenia observed there than in Australia/New Zealand.
- Other material risks include clinical-trial safety, efficacy, enrollment and regulatory uncertainty; manufacturing scale-up and facility execution; dependence on collaboration revenue; competition and intellectual-property claims; currency conversion and PRC regulatory risks; and potential volatility in investment values. The filing reported no material pending legal proceeding and no off-balance-sheet arrangements.
- Controls: management deemed disclosure controls effective as of June 30, but reported an unresolved material weakness in internal control over financial reporting related to insufficient experienced financial-reporting personnel. Remediation was underway.
- Commitments included $12.451 million of capital commitments for property and equipment and $7.184 million of operating lease commitments. Subsequent to quarter-end, the company granted approximately 19.155 million options to employees and consultants.
Most important facts for investors to verify
- Whether clinical progress and safety data support continued development of BGB-3111, BGB-A317, BGB-290 and BGB-283, particularly the BGB-283 accrual pause and its resolution.
- Actual cash burn and whether available cash and investments will support the stated runway amid rising R&D spending and capital commitments.
- Progress on financing plans, the Suzhou manufacturing facility, and the $10.553 million secured bank loan and repayment schedule.
- Terms and remaining economics of the Merck KGaA arrangements, including milestone and royalty potential after the BGB-290 rights repurchase.
- Remediation of the financial-reporting material weakness and the effects of post-quarter option grants on potential dilution.